Related Experiment Video

Updated: Oct 3, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.4K

LRP6 Polymorphisms Is Associated With Sudden Cardiac Death in Patients With Chronic Heart Failure in the Chinese Han

Qi Guo1, Yiwei Lai1, Jianmin Chu2

  • 1Department of Cardiology, National Clinical Research Center for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Frontiers in Cardiovascular Medicine
|February 21, 2022
PubMed

Insights

Genetic variations in Low-density lipoprotein receptor-related protein 6 (LRP6) are linked to increased sudden cardiac death (SCD) risk in chronic heart failure (CHF) patients. The LRP6 SNP rs2302684 T>A variant predicts higher mortality and SCD in this population.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Low-density lipoprotein receptor-related protein 6 (LRP6) is crucial for cardiovascular homeostasis.
  • LRP6 deficiency is linked to arrhythmias, but its genetic variants' role in sudden cardiac death (SCD) is unclear.

Purpose of the Study:

  • To investigate the association between common LRP6 genetic variants and the prognosis of chronic heart failure (CHF) patients.
  • To evaluate the impact of LRP6 polymorphisms on survival outcomes in CHF.

Main Methods:

  • A cohort of 1,437 CHF patients was recruited from 10 Chinese hospitals between July 2005 and December 2009.
  • The single-nucleotide polymorphism (SNP) rs2302684 in LRP6 was genotyped.
  • Patients were followed for a median of 61 months to assess all-cause death and SCD.

Main Results:

  • Patients with the A allele of rs2302684 exhibited a significantly increased risk of all-cause death (adjusted HR 1.452) and SCD (adjusted HR 1.783).
  • The T>A variation at SNP rs2302684 in LRP6 was associated with higher risks of all-cause mortality and SCD in CHF patients.
  • Out of 1,437 patients, 546 (38.0%) died, including 201 (36.8%) SCD cases.

Conclusions:

  • The LRP6 SNP rs2302684 T>A variant is a significant predictor of increased all-cause death and SCD in CHF patients.
  • LRP6 may serve as a novel biomarker for predicting SCD risk.
  • LRP6 warrants further investigation as a potential therapeutic target for SCD prevention in CHF populations.

Keywords:
LRP6chronic heart failureprognosissingle-nucleotide polymorphismsudden cardiac death

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.5K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
77
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
99
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.5K